0000950170-24-030485.txt : 20240313 0000950170-24-030485.hdr.sgml : 20240313 20240313060411 ACCESSION NUMBER: 0000950170-24-030485 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGH SUSANNA GATTI CENTRAL INDEX KEY: 0001691005 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24744502 MAIL ADDRESS: STREET 1: 75 LORIMER ROAD CITY: BELMONT STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-03-08 0001818794 Dyne Therapeutics, Inc. DYN 0001691005 HIGH SUSANNA GATTI 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false Chief Operating Officer true Common Stock 2024-03-08 4 S false 26908 26.66 D 159383 D Common Stock 2024-03-08 4 S false 291 27.41 D 159092 D Common Stock 2024-03-11 4 S false 2292 25.70 D 156800 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.32 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.39 to $27.42, inclusive. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. Includes 145,829 unvested RSUs. /s/ Richard Scalzo, Attorney-in-Fact 2024-03-12